BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao B, Zhao H. Incidence and risk of regorafenib-induced hepatotoxicity. Oncotarget 2017;8:84102-11. [PMID: 29137408 DOI: 10.18632/oncotarget.21106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Colombatto P, Demirtas CO, Ricco G, Civitano L, Boraschi P, Scalise P, Cavallone D, Oliveri F, Romagnoli V, Bleve P, Coco B, Salvati A, Urbani L, Bonino F, Brunetto MR. Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib. Cancers (Basel) 2021;13:2064. [PMID: 33922938 DOI: 10.3390/cancers13092064] [Reference Citation Analysis]
2 Argiles G, Arnold D, Prager G, Sobrero AF, Van Cutsem E. Maximising clinical benefit with adequate patient management beyond the second line in mCRC. ESMO Open 2019;4:e000495. [PMID: 31231561 DOI: 10.1136/esmoopen-2019-000495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Maeda A, Irie K, Ando H, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Aoki M, Inaguma K, Kajita M, Fujimura A, Fukushima S. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms. Cancer Chemother Pharmacol. 2019;83:107-113. [PMID: 30368586 DOI: 10.1007/s00280-018-3710-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xie G, Gong Y, Wu S, Li C, Yu S, Wang Z, Chen J, Zhao Q, Li J, Liang H. Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers. Adv Ther 2019;36:1986-98. [DOI: 10.1007/s12325-019-01013-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]